… -agent enzalutamide and … enzalutamide may result in reactivation of AR, so that disrupting
this adaptive feedback loop by combining with abiraterone would reinduce enzalutamide …

… Patients were randomly assigned in a 1:1:1 ratio to receive enzalutamide plus leuprolide (combination
group, double-blind), placebo plus leuprolide (leuprolide-alone group, double-…

… in earlier stages of the disease, and to investigate the optimal sequencing and
combination of enzalutamide with other standard and novel therapies for prostate cancer. …

… and enzalutamide, respectively, significantly delayed the development of enzalutamide-resistant
prostate cancer … provides a strong rationale for clinical evaluation of this combination. …

… Indeed, novel androgen blocking therapies, including enzalutamide and abiraterone acetate
in combination with prednisone, are among several new treatments for mCRPC that have …

… A possible combinatorial treatment regimen is currently being tested in trials that evaluate
the efficacy of enzalutamide in combination with taxane-based chemotherapeutics for the …

… ) and enzalutamide monotherapy versus placebo plus leuprolide (leuprolide alone) in … -sensitive
prostate cancer after definitive therapy. In EMBARK, enzalutamide combination and …

… -resistant prostate cancer (CRPC) revealed that enzalutamide … The combination of docetaxel
and enzalutamide may be an … evaluate enzalutamide combined with other prostate cancer …

… Here we present a phase I clinical trial of enzalutamide combined with the AKT inhibitor
capivasertib in patients with mCRPC and show that this regimen is safe and tolerable. …

5000 Background: Co-targeting the androgen receptor (AR) and paracrine androgen biosynthesis
in mCRPC may be more effective than either alone. This study aims to evaluate safety…